Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
George Dailey, Aakif Ahmad, Sarit Polsky & Viral Shah. (2016) A novel option for prandial insulin therapy: inhaled insulin. Postgraduate Medicine 128:8, pages 839-847.
Read now
Read now
Articles from other publishers (10)
Nihad Kharrat HeluAbdulhakim Nattouf. (2023) A Comparison of Efficacy among Syrian diabetic patients treated with Empagliflozin versus Dapagliflozin, a Randomized, Triple-blind, Two-period crossover study. Research Journal of Pharmacy and Technology, pages 4642-4648.
Crossref
Crossref
Khaled Hameed Husain, Saud Faisal Sarhan, Haya Khaled Ali Abdulla AlKhalifa, Asal Buhasan, Abu Saleh Md Moin & Alexandra E. Butler. (2023) Dementia in Diabetes: The Role of Hypoglycemia. International Journal of Molecular Sciences 24:12, pages 9846.
Crossref
Crossref
George Dailey, Timothy Reid, John White, Jason Chao, Fang L. Zhou, Sachin Paranjape & Paulos Berhanu. (2018) Improved glycaemic control and lower hypoglycaemia risk with reduced prior oral antidiabetes drug therapy in patients with type 2 diabetes treated with insulin glargine 300 U/mL. Endocrinology, Diabetes & Metabolism 1:4, pages e00035.
Crossref
Crossref
Tomoyuki Iwasaki, Takaomi Kessoku, Takuma Higurashi, Masataka Taguri & Masato Yoneda. (2018) Low body mass index and old age are useful in predicting the hemoglobin A1c-lowering effect of switching from sitagliptin to dulaglutide in Japanese patients with type 2 diabetes mellitus: a single-center, open-label, single-arm, pilot study. Diabetology International 9:3, pages 189-195.
Crossref
Crossref
Dandan Li, Tiansheng Wang, Su Shen, Zhenwei Fang, Yue Dong & Huilin Tang. (2017) Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism 19:3, pages 348-355.
Crossref
Crossref
Tomoyuki Iwasaki & Masato Yoneda. (2015) Baseline low-density lipoprotein cholesterol predicts the hemoglobin A1c-lowering effect of dapagliflozin in Japanese patients with type 2 diabetes mellitus. Diabetology International 7:1, pages 77-82.
Crossref
Crossref
S. Lane Slabaugh, Yihua Xu, Jane N. Stacy, Jean C. Baltz, Yunus A. Meah, Jean Lian, D. Chad Moretz & Jonathan R. Bouchard. (2015) Antidiabetic Treatment Patterns in a Medicare Advantage Population in the United States. Drugs & Aging 32:2, pages 169-178.
Crossref
Crossref
Lizheng Shi, Hui Shao, Yingnan Zhao & Nina A Thomas. (2014) Is hypoglycemia fear independently associated with health-related quality of life?. Health and Quality of Life Outcomes 12:1.
Crossref
Crossref
Chris R. Triggle & Hong Ding. (2014) Cardiovascular impact of drugs used in the treatment of diabetes. Therapeutic Advances in Chronic Disease 5:6, pages 245-268.
Crossref
Crossref
J. Bolinder, Ö. Ljunggren, L. Johansson, J. Wilding, A. M. Langkilde, C. D. Sjöström, J. Sugg & S. Parikh. (2014) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes, Obesity and Metabolism 16:2, pages 159-169.
Crossref
Crossref